New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2013
13:40 EDTONXX, AMGNOnyx Pharmaceuticals calls active on deal speculation
Onyx Pharmaceuticals (ONXX) September 125 and 130 calls are active on total call volume of 42K contracts (6K puts) on deal speculation with Amgen (AMGN). September call overall option implied volatility is at 62, October is at 49, November is at 43; compared to its 26-week average of 37 according to Track Data, suggesting large price movement.
News For ONXX;AMGN From The Last 14 Days
Check below for free stories on ONXX;AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
12:50 EDTAMGNEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 28, 2014
09:18 EDTAMGNAmgen anounces Evolocumab YUKAWA-2 study meets co-primary endpoints
Subscribe for More Information
09:04 EDTAMGNAmgen submits evolocumab BLA to FDA
Subscribe for More Information
August 27, 2014
09:20 EDTAMGNFDA grants Amgen priority review designation for ivabradine
Amgen announced the U.S. Food and Drug Administration has granted priority review designation for ivabradine for the treatment of chronic heart failure. Ivabradine is an oral drug that inhibits the If current in the sinoatrial node, the body's cardiac pacemaker. The New Drug Application is based on global clinical trial data from the Phase 3 SHIFT, or Systolic Heart failure treatment with the If inhibitor ivabradine Trial), study. The SHIFT study compared ivabradine to placebo on top of standard-of-care therapies, including beta-blockers, in more than 6,500 patients in sinus rhythm with reduced left ventricular function and heart rate greater than 70 beats per minute.
August 26, 2014
11:21 EDTAMGNAmgen added to short term buy list at Deutsche Bank
Subscribe for More Information
08:04 EDTONXXOnyx treatment of Waldenstrom's macroglobulinemia granted orphan status
Oprozomib was granted FDA orphan drug designation as a treatment of Waldenstrom's macroglobulinemia, the agency stated. Reference Link
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
August 19, 2014
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
17:25 EDTAMGNAmgen announces AMG 416 study met its primary and all secondary endpoints
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, SHPT, in patients with chronic kidney disease,CKD, receiving hemodialysis, met its primary and all secondary endpoints. "The results from this second Phase 3 study help to confirm that AMG 416 could become an important new treatment option for dialysis patients with secondary hyperparathyroidism," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite the variety of options available for the treatment of this disease, an unmet need remains for an intravenous therapy that can be administered along with hemodialysis. We look forward to sharing results of a head-to-head study evaluating AMG 416 compared to cinacalcet next year."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use